Howard Jack West, MD, of the Swedish Cancer Institute, summarizes three important papers: anlotinib as third-line treatment for refractory advanced non–small cell lung cancer; the EGFR exon 20 mutation as a prognostic/predictive biomarker; and EGFR exon 18 mutations as molecular predictors of sensitivity to afatinib or neratinib (Abstracts ORAL 3.01, 3.02, and 3.03).
James L. Mulshine, MD, of Rush University Medical Center, discusses the profound challenges of implementing national CT screening to ensure delivery of high-quality, best-practice ...
Tony Mok, MD, of The Chinese University of Hong Kong, and Fred R. Hirsch, MD, PhD, of University of Colorado Health Science Center discuss the highlights of the fe...
Nagashree Seetharamu, MD, of the North Shore LIJ Health System, discusses serum AGA-signatures that may provide a minimally invasive test for early detection of lung cancer risk (A...
Alice T. Shaw, MD, PhD, of Massachusetts General Hospital, summarizes efficacy and safety data from studies on crizotinib, brigatinib, and alectinib for ALK-positive non–s...
Roy S. Herbst, MD, PhD, of the Smilow Cancer Hospital at Yale Cancer Center, discusses his findings of a phase III study comparing carboplatin/paclitaxel or carboplatin/paclitaxel/...